Becton, Dickinson and Company (NYSE:BDX – Get Free Report) and Brainsway (NASDAQ:BWAY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Risk and Volatility
Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Becton, Dickinson and Company and Brainsway, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Becton, Dickinson and Company | 1 | 8 | 8 | 1 | 2.50 |
| Brainsway | 0 | 2 | 5 | 0 | 2.71 |
Becton, Dickinson and Company presently has a consensus target price of $197.47, indicating a potential downside of 7.00%. Brainsway has a consensus target price of $18.20, indicating a potential upside of 68.44%. Given Brainsway’s stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than Becton, Dickinson and Company.
Earnings and Valuation
This table compares Becton, Dickinson and Company and Brainsway”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Becton, Dickinson and Company | $21.84 billion | 2.68 | $1.68 billion | $4.14 | 51.29 |
| Brainsway | $52.22 million | 8.33 | $7.57 million | $0.44 | 24.56 |
Becton, Dickinson and Company has higher revenue and earnings than Brainsway. Brainsway is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Becton, Dickinson and Company and Brainsway’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Becton, Dickinson and Company | 4.52% | 14.79% | 6.93% |
| Brainsway | 15.65% | 12.74% | 8.17% |
Insider and Institutional Ownership
87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Becton, Dickinson and Company beats Brainsway on 8 of the 15 factors compared between the two stocks.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
About Brainsway
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
